A new MRI scan for GIST on imatinib
Part of Cancer, Digestive system clinical trials.
This study uses a special type of MRI to see how well imatinib, a targeted cancer pill, is working in people with GIST. It may help doctors understand which patients are responding best to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a GIST through a biopsy.
- You are scheduled to receive or are already taking imatinib.
- You have at least one tumor that can be seen on a scan.
- You are 18 years old or older.
- You are not pregnant or breastfeeding, and can safely have an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies advanced GIST cancers that have stopped responding to all four standard treatments. It uses PET-CT scans and genetic testing of tumor tissue to understand resistance, helping to find the best next treatment.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests whether taking imatinib before surgery can shrink a rectal GIST (a rare tumor) and make “rectum-sparing” surgery more possible. It is for people whose tumor has a specific c-KIT gene mutation and who can’t safely get a complete local resection at the start.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Hear when a new Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.